Top Insights
Health
globalreutersNovember 25, 20241 Mins read
FDA Nod for BridgeBio Brings New Competition to Blockbuster Pfizer Cardio Drug
globalreutersNovember 25, 20241 Mins read 
BridgeBio Pharma claims its drug, Attruby, has an edge over a Pfizer drug as a treatment for cardiomyopathy caused by transthyretin-mediated amyloidosis. But new competition to both products could come soon from Alnylam Pharmaceuticals, now set to receive an FDA decision in this indication by late March.
The post FDA Nod for BridgeBio Brings New Competition to Blockbuster Pfizer Cardio Drug appeared first on MedCity News.
Recent Posts
Categories
Related Articles
What is HEMA?
The Pink Sheet reports on a new international health technology assessment (HTA)...
How Pending Health-Related Lawsuits Could be Impacted by the Incoming Trump Administration
This brief provides an overview of current lawsuits in health policy including...
These 3 Mindset Shifts Will Help Providers Deliver Consumer-Driven Care, Investor Says
One of the most important things providers can do on the journey...
IVF Treatment in India:A complete Guide to Costs, Success Rates and Clinics
Thinking about in-vitro fertilization (IVF) but unsure about costs, success rates, and...
Leave a comment